Alembic Pharmaceuticals announces USFDA Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg
Bengaluru, 19th June 2024: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food &
Read More